再発悪性神経膠腫とは、治療後に腫瘍が再発することを指します。症状としては、脊髄の胸部にできた腫瘍による胸痛、勃起不全、体温の変化を感じられないこと、筋肉のコントロールができないこと、腸や膀胱のコントロールができないこと、しびれや麻痺、脊髄の頸部にできた腫瘍による腕、首、腰、足の痛み、手足や上半身の脱力感などです。治療には化学療法や放射線療法が行われます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignant Glioma - Overview
Recurrent Malignant Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignant Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
Candel Therapeutics Inc
Hebei Senlang Biotechnology Co Ltd
Immunomic Therapeutics Inc
Moleculin Biotech Inc
Oblato Inc
PharmAbcine Inc
Smerud Medical Research International AS
Stella Pharmaceuticals Pvt Ltd
Sumitomo Pharma Co Ltd
Recurrent Malignant Glioma - Drug Profiles
2141 V-11 - Drug Profile
Product Description
Mechanism Of Action
2X-111 - Drug Profile
Product Description
Mechanism Of Action
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
borofalan - Drug Profile
Product Description
Mechanism Of Action
CAN-3110 - Drug Profile
Product Description
Mechanism Of Action
disufenton sodium - Drug Profile
Product Description
Mechanism Of Action
DSP-0390 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile
Product Description
Mechanism Of Action
ITI-1000 - Drug Profile
Product Description
Mechanism Of Action
Memory Enriched T Cells - Drug Profile
Product Description
Mechanism Of Action
SENL-006 - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile
Product Description
Mechanism Of Action
WP-1066 - Drug Profile
Product Description
Mechanism Of Action
Recurrent Malignant Glioma - Dormant Projects
Recurrent Malignant Glioma - Discontinued Products
Recurrent Malignant Glioma - Product Development Milestones
Featured News & Press Releases
Apr 22, 2022: Moleculin obtains FDA clearance for Phase I glioma treatment trial
Dec 06, 2017: Moleculin's WP1066 Drug receives $2 million Private Grant
Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance
Apr 21, 2017: Japan's Ministry of Health, Labour and Welfare Announces SAKIGAKE Designation For Stella Pharma's Cancer Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Recurrent Malignant Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Recurrent Malignant Glioma - Pipeline by Candel Therapeutics Inc, 2022
Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, 2022
Recurrent Malignant Glioma - Pipeline by Moleculin Biotech Inc, 2022
Recurrent Malignant Glioma - Pipeline by Oblato Inc, 2022
Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, 2022
Recurrent Malignant Glioma - Pipeline by Smerud Medical Research International AS, 2022
Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, 2022
Recurrent Malignant Glioma - Pipeline by Sumitomo Pharma Co Ltd, 2022
Recurrent Malignant Glioma - Dormant Projects, 2022
Recurrent Malignant Glioma - Dormant Projects, 2022 (Contd..1)
Recurrent Malignant Glioma - Discontinued Products, 2022
List of Figures
Number of Products under Development for Recurrent Malignant Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
